Nisa Investment Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$906 Hold
387
﹤0.01% 2765
2025
Q4
$522 Hold
387
﹤0.01% 2811
2025
Q3
$584 Hold
387
﹤0.01% 2830
2025
Q2
$449 Buy
387
+60
+18% +$79 ﹤0.01% 2889
2025
Q1
$520 Sell
327
-543
-62% -$1.17K ﹤0.01% 2785
2024
Q4
$2.64K Buy
870
+749
+619% +$2.46K ﹤0.01% 2408
2024
Q3
$445 Sell
121
-4,696
-97% -$17.1K ﹤0.01% 2739
2024
Q2
$19.7K Buy
4,817
+4,131
+602% +$46.1K ﹤0.01% 1950
2024
Q1
$10.8K Buy
686
+121
+21% +$1.66K ﹤0.01% 2023
2023
Q4
$8.56K Hold
565
﹤0.01% 2068
2023
Q3
$11.3K Sell
565
-1,020
-64% -$25.9K ﹤0.01% 2147
2023
Q2
$44.7K Buy
1,585
+340
+27% +$8.16K ﹤0.01% 1786
2023
Q1
$21K Buy
1,245
+30
+2% +$608 ﹤0.01% 2002
2022
Q4
$24K Sell
1,215
-23
-2% -$495 ﹤0.01% 2015
2022
Q3
$31K Buy
1,238
+38
+3% +$1.04K ﹤0.01% 1919
2022
Q2
$34K Buy
1,200
+20
+2% +$530 ﹤0.01% 1873
2022
Q1
$54K Sell
1,180
-180
-13% -$9.71K ﹤0.01% 1819
2021
Q4
$78K Sell
1,360
-320
-19% -$24.8K ﹤0.01% 1603
2021
Q3
$112 Hold
1,680
﹤0.01% 1651
2021
Q2
$89 Buy
+1,680
New +$90K ﹤0.01% 1750

Other funds holding ZNTL

Nisa Investment Advisors's ZNTL Position: Q1 2026 in Review

Nisa Investment Advisors held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 387 shares worth $906. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

Nisa Investment Advisors first reported a position in ZNTL in Q2 2021 and has held it in 20 quarters since. The position peaked at $78K in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Nisa Investment Advisors held 387 shares of Zentalis Pharmaceuticals worth $906 as of Q1 2026.
  • Nisa Investment Advisors left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2765 holding.
  • Nisa Investment Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Nisa Investment Advisors's Zentalis Pharmaceuticals position peaked at $78K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.